INBX had $199.5 million in cash and is advancing drug studies and launch preparations. Its loss widened, and interest and launch-preparation costs rose, so the report gives mixed signals.
The cash balance supports continued drug studies and preparation for a possible launch. Updated study results are due soon, with other trial results expected in 2027. But the quarterly loss widened, loan interest costs rose, and launch-preparation costs increased. Those developments point in different directions.
Pfizer paid $2.0 million for a non-exclusive license to certain Inhibrx patent rights. The filing gives no expected sales or other effect for Pfizer, so it shows no clear change in its outlook.
Follow Inhibrx Biosciences, Inc. (INBX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for INBX